Titan Pharma: Titan Pharma (TTNP) Misses Q4 EPS by 31c, Revenues Beat
Titan Pharma (NASDAQ: TTNP) reported Q4 EPS of ($0.62), $0.31 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $300 thousand.
Read full article »
Titan Pharma manufactures and markets pharmaceutical raw materials, drug intermediates, and finished formulations.
Read more